health

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

The vaccine reportedly thwarted the cancer’s return and spread.

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

TL;DR

  • Moderna and Merck's mRNA cancer vaccine (intismeran) combined with Keytruda showed success in a Phase 3 trial for melanoma.
  • The combination therapy extended recurrence-free survival (RFS) and distant metastasis-free survival (DMFS).
  • The trial was placebo-controlled and double-blind, involving 1,137 patients with surgically removed stage IIB-IV melanoma.
  • The mRNA vaccine targets up to 34 mutations in a patient's cancer cells, presenting them as antigens to the immune system.
  • Experts consider this a landmark moment for neoantigen therapy and mRNA-based cancer treatments, though more detailed data is needed.